Compare Incyte Corporation (INCY) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Solar ETF — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Invesco Solar ETF trades at $52.46. The key difference: Incyte Corporation is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| INCY | TAN | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $73.95 |
52-Week Low | $81.61 | $36.62 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
TAN trades at $53.3, up 2.78% over 24 hours, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buys. The ETF faces volatility with a beta of 1.41, as noted by The Motley Fool on August 11, 2026, and recent polysilicon tariffs under the Trump administration have spurred mixed reactions, boosting U.S. solar stocks but raising costs for import-dependent firms, per Reuters on August 7, 2026.
Outlook is cautious due to regulatory uncertainties and high expense ratios, but long-term growth potential exists from AI-driven energy demand. Risks include policy shifts and competition, while institutional sentiment is divided with recent downgrades highlighting valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
